Decapeptide-12 is a synthetic peptide (with sequence Tyr-Arg-Ser-Arg-Lys-Tyr-Ser-Ser-Trp-Tyr) known under the trade name Lumixyl™ that acts as a tyrosinase inhibitor, the enzyme responsible for the production of melanin in the skin. In fact, in vitro studies show that Lumixyl is 5.5 times more effective than hydroquinone at equivalent doses in moderating melanin.
Developed by dermatological researchers at Stanford University, Decapeptide-12, an innovative, targeted peptide, has been shown in in vitro studies to reduce melanin expression, yielding a blended, more even complexion across all skin types. It is a practical approach for long-term hyperpigmentation management suitable for all skin types.
In addition, Decapeptide-12 allows for the avoidance of common adverse effects in hyperpigmentation and dark spot treatment. It is effective even at low concentrations and begins working at concentrations as low as 0.01%. Combined with AHAs like glycolic acid, it provides noticeable results and is indicated for the treatment of mild-to-moderate melasma.
Preliminary clinical study results are being evaluated in large confirmatory trials and demonstrate the peptide's ability to yield visible improvements in melasma appearance. Study participants included persons who had previously been unsuccessful after 6-month terms with a hydroquinone, retinol, and steroid regimen but reported visible improvements with Decapeptide-12 in as little as 8 weeks, with a 50% improvement after 16 weeks.
